FDA Grants Orphan Drug Designation to KB407, Potential Gene Therapy for CF
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to KB407, Krystal Biotech’s potential inhaled gene therapy for the treatment of cystic fibrosis (CF). “We are pleased to receive Orphan Drug Designation for KB407 to treat cystic fibrosis as…